Mirae Asset Global Investments Co. Ltd. Has $514,000 Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.5% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 16,713 shares of the specialty pharmaceutical company’s stock after buying an additional 868 shares during the period. Mirae Asset Global Investments Co. Ltd. owned about 0.05% of Collegium Pharmaceutical worth $514,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Collegium Pharmaceutical by 320.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 3,776 shares of the specialty pharmaceutical company’s stock worth $116,000 after acquiring an additional 2,877 shares during the last quarter. Versor Investments LP acquired a new stake in shares of Collegium Pharmaceutical during the third quarter valued at about $207,000. SG Americas Securities LLC bought a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $221,000. O Shaughnessy Asset Management LLC increased its stake in shares of Collegium Pharmaceutical by 14.3% in the third quarter. O Shaughnessy Asset Management LLC now owns 11,509 shares of the specialty pharmaceutical company’s stock valued at $257,000 after buying an additional 1,440 shares during the period. Finally, Ritholtz Wealth Management bought a new position in Collegium Pharmaceutical in the 4th quarter valued at approximately $286,000.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the stock. Needham & Company LLC reissued a “buy” rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Piper Sandler restated an “overweight” rating and issued a $39.00 price objective (up from $37.00) on shares of Collegium Pharmaceutical in a report on Friday, February 23rd. Jefferies Financial Group reaffirmed a “hold” rating and set a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. Finally, Truist Financial increased their price target on Collegium Pharmaceutical from $37.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, February 26th. Two research analysts have rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $39.00.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.84 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The firm has a market cap of $1.17 billion, a price-to-earnings ratio of 30.37 and a beta of 1.03. The company’s fifty day simple moving average is $37.06 and its 200 day simple moving average is $31.18. Collegium Pharmaceutical, Inc. has a 12-month low of $20.83 and a 12-month high of $40.95.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.20 by $0.25. The company had revenue of $149.75 million for the quarter, compared to analyst estimates of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, analysts expect that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.